Breast Cancer Clinical Trials & Research at Providence Medical Group

In the U.S., breast cancer is the second most common cancer in women after skin cancer. It can occur in both men and women. The most common type of breast cancer is ductal carcinoma, which begins in the cells of the ducts. Breast cancer can also begin in the cells of the lobules and in other tissues in the breast. Invasive breast cancer is breast cancer that has spread from where it began in the ducts or lobules to surrounding tissue.

Providence Medical Group is currently enrolling patients for the following breast cancer clinical trials:


A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Nab-Paclitaxel or Paclitaxel versus Nab-Paclitaxel or Paclitaxel in Previously Untreated Patients with Metastatic Triple-Negative Breast Cancer

Treatment agent: Magrolimab + Nap-Paclitaxel or Paclitaxel vs. Nab-Paxlitaxel or Paclitaxel
PI: Jarrod Holmes, MD
Study Coordinator: Teresa Lund
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04958785?term=NCT04958785&draw=2&rank=1
Sponsor: Gilead Sciences


A Phase I/IIa Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination with Pembrolizumab (BriaCell Rollover)

Treatment agent: SV-BR-1-GM + Pembrolizumab
PI: Jarrod Holmes, MD
Study Coordinator: Kim
Resources and Links: clinicaltrials.gov NCT No: NCT03328026


A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Unresectable and/or Metastatic Solid Tumors Harboring HER2 Activating Mutations Regardless of Tumor Histology

Treatment agent: Trastuzumab Deruxtecan
PI: Ian Anderson, MD
Study Coordinator: Camille Shaffer // Camille.Shaffer@stjoe.org // (707) 521-3809 ext. 1182
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04639219?term=04639219&draw=2&rank=1
Sponsor: AstraZeneca


A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator’s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)

Treatment agent: Trastuzumab deruxtecan
PI: Manasa Vulshi, MD
Study Coordinator: Camille Shaffer // Camille.Shaffer@stjoe.org // (707) 521-3809 ext. 1182
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04494425?term=04494425&draw=2&rank=1
Sponsor: AstraZeneca


Study to Assess the Effect of PF_06946860 on Appetite Following Subcutaneous Administration to Patients with Anorexia and Advanced Cancer

Treatment agent: PF-06946860
PI: Sara Keck, MD
Study Coordinator: Melissa Phillips // Melissa.Phillips2@stjoe.org// (707) 521-3833 ext. 1313
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04803305?term=PF-06946860&draw=2&rank=2
Sponsor: Pfizer


A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Unresectable and/or Metastatic Solid Tumors Harboring HER2 Activating Mutations Regardless of Tumor Histology

Treatment agent: Berzosertib, Topotecan Hydrochloride
PI: Ian Anderson, MD
Study Coordinator: Camille Shaffer
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04639219?term=04639219&draw=2&rank=1
Sponsor: AstraZeneca


Our Providers

Our Locations